Drug intelligence / Profile preview

biliverdin IXα

Development stage
Preclinical
Lead developer
University of Mississippi Medical Center
Modality
Small Molecules
Administration
Intraperitoneal, Parenteral
01

Overview

Biliverdin IXα is a naturally occurring green tetrapyrrolic bile pigment and an intermediate product of heme catabolism. It is generated by the cleavage of heme at the alpha-methane bridge, a reaction catalyzed by the rate-limiting enzyme heme oxygenase (HO-1 and HO-2). Biliverdin IXα is subsequently reduced to bilirubin IXα by the cytosolic enzyme biliverdin reductase A (BLVRA). Biliverdin IXα exhibits potent antioxidant, anti-inflammatory, and cytoprotective properties. In preclinical models, administration of biliverdin IXα has been shown to attenuate angiotensin II-induced hypertension, improve renal hemodynamics, and prevent intimal hyperplasia following vascular injury. Its therapeutic effects are primarily mediated through its conversion to bilirubin, which acts as a scavenger of reactive oxygen species (ROS) and a ligand for peroxisome proliferator-activated receptor alpha (PPARα), as well as through direct signaling via biliverdin reductase to modulate inflammatory pathways such as TLR4 and IL-10.

Other names
biliverdinbiliverdin IX alphabiliverdin IX-alphabiliverdin-IX-alphadehydrobilirubinuteroverdin
02

Targets

AHR (Aryl hydrocarbon receptor)BLVRA (Biliverdin reductase A)PRKCD (Protein kinase C delta)

Beyond the preview

Go deeper on biliverdin IXα.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on biliverdin IXα.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call